BIA Separations signs agreement to commercialise novel elution technology

26 Feb 2020

Agreement gives BIA Separations access to proprietary technology to better preserve integrity, infectivity and potency of immunoaffinity-purified viral vectors for gene therapy.

BIA Separations has signed a licensing agreement with the University of Zagreb to commercialize a novel elution method that helps preserve the integrity, infectivity and potency of viruses during immunoaffinity purification.

BIA Separations signs agreement to commercialise novel elution technology

The University of Zagreb will provide BIA Separations with access to proprietary technology, while BIA Separations will market the technology to biopharma, biotech and life science industries globally. As part of the agreement, research teams from both organisations will collaborate to develop follow-on technologies to support the purification of viruses and viral vectors for research and clinical use.

One of the key disadvantages of the immunoaffinity chromatography is partial degradation of viral particles as a result of low pH conditions required for the elution. The technology overcomes this by using a concentrated solution of specifically selected amino acids and their salts, maintaining a neutral pH (6.0 – 8.0), which results in the highly effective elution from immunoaffinity chromatographic support of intact and functional viruses for gene therapy application.

BIA Separations will commercialize the technology through sales of the its core separations products and services, or as individual license agreements.

Aleš Štrancar, CEO of BIA Separations commented: “BIA Separations monolithic column technology is now well established and following this success we are focussed on providing customers with a “one-stop-shop” for the manufacture of gene therapy vectors, vaccines, exosomes, DNA/RNA and any novel complex biopharma product. To achieve fully integrated upstream and downstream processing with robust in-process control we are collaborating with other leaders in the industry to access the latest technologies and products. This agreement with the University Zagreb is one of a number currently in the pipeline and supports our ultimate goal.”

Professor Miljenko Šimpraga, Vice-rector for Innovation, Technology Transfer and Communication at the University of Zagreb added: “The University of Zagreb is pleased to see solutions developed by our researchers contributing to improvements in medical biotechnology, and being brought closer to users through our work with innovation-oriented industry partners such as BIA Separations. As a research university, this is an important achievement which is fully aligned with our aim to create a positive impact on society.”

Read More

Related news

Piramal acquires solid oral dosage drug product facility from G&W Laboratories

Piramal acquires solid oral dosage drug product facility from G&W Laboratories

22 Jun 2020

The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.

Read more 
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

22 Jun 2020

The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.

Read more 
Sanofi to build EUR 490 million vaccine production facility in France

Sanofi to build EUR 490 million vaccine production facility in France

16 Jun 2020

The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines

Read more 
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

8 Jun 2020

Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.

Read more 
Emergent bags $628 million landmark CDMO deal to produce COVID-19 vaccine candidates

Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates

2 Jun 2020

The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.

Read more 
Changes needed to prevent controversial pay-for-delay pharma deals

Changes needed to prevent controversial pay-for-delay pharma deals

26 May 2020

Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

Read more 
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

26 May 2020

SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

Read more 
AbCellera and Lilly seal multi-year antibody discovery collaboration

AbCellera and Lilly seal multi-year antibody discovery collaboration

25 May 2020

AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.

Read more 
HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

25 May 2020

The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more